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STATUS ANTIOKSIDAN DAN KESAN PEMBERIAN PECAHAN YANG 
KAYA DENGAN TOKOTRIENOL (TRF) KE ATAS ENZIM ANTIOKSIDAN 
DAN PERKEMBANGAN HIPERTENSI DALAM TIKUS HIPERTENSI 
SPONTAN (SHR) 
 
ABSTRAK 
 
Walaupun stress oksidatif telah dikaitkan dengan patogenesis hipertensi 
dalam tikus hipertensi spontan (SHR), status sebenar enzim antioksidan (AOE) dan 
beberapa parameter yang berkaitan seperti glutation total (GSH), status antioksidan 
total (TAS),  malondialdehid (MDA), serta tahap α-, δ- dan γ- tokotrienol plasma 
semasa perkembangan hipertensi masih tidak jelas. Oleh itu, kajian ini memeriksa 
parameter tersebut di ginjal SHR dari umur 2 hingga 16 minggu, dan kesan 
pemberian pecahan yang kaya dengan tokotrienol (TRF) terhadap parameter tersebut 
serta perkembangan tekanan darah tinggi dalam spesis ini. 
 
Berbanding dengan tikus WKY yang berpadanan umur, aktiviti katalas 
(CAT) lebih tinggi secara signifikan seawal umur 2 minggu, manakala aktiviti 
glutation peroksida (GPx) lebih rendah secara signifikan bermula dari umur 4 
minggu dalam SHR. Ekspresi mRNA juga menunjukkan perubahan yang serupa 
dengan aktivitinya. Tahap TAS lebih tinggi secara signifikan dalam SHR pada umur 
4, 10, 12 dan 16 minggu, manakala tiada perbezaan pada tahap MDA kecuali pada 
umur 16 minggu apabila tahapnya lebih tinggi dalam SHR. Tahap plasma α-
tokotrienol lebih rendah secara signifikan sejak umur 6 minggu manakala tahap γ-
tokotrienol lebih rendah secara signifikan pada  umur 12 dan 16 minggu dalam SHR. 
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Berbanding dengan SHR yang berpadanan umur dan tidak diberi TRF, tahap 
plasma α-, γ- dan δ- tokotrienol lebih tinggi secara signifikan dalam SHR yang diberi 
TRF. Purata tekanan darah sistolik lebih rendah secara signifikan pada umur 6 
minggu dalam SHR yang diberi TRF, tetapi lebih tinggi secara signifikan pada umur 
12 dan 16 minggu. Aktiviti glutation reduktas (GR) di ginjal lebih tinggi pada umur 
6, 8 dan 10 minggu, dan aktiviti glutation S-transferas (GST) di ginjal juga lebih 
tinggi pada umur 6, 10 dan 12 minggu dalam SHR yang diberi TRF. Tahap MDA 
secara konsisten lebih rendah dalam SHR yang diberi TRF. Pemberian TRF kepada 
tikus WKY tidak memberi kesan ke atas tekanan darah atau aktiviti AOE primer 
kecuali aktiviti dan tahap ekspresi mRNA superoksida dismutas (SOD) yang lebih 
rendah dalam SHR yang diberi TRF. Walaubagaimanapun, aktiviti GR adalah lebih 
tinggi secara signifikan pada umur 6, 8 dan 10 minggu dalam tikus WKY yang diberi 
TRF. 
 
Kesimpulannya, oleh kerana terdapat perubahan ekspresi dan aktiviti 
sebilangan AOE sejak umur 2 minggu iaitu sebelum peningkatan sebenar tekanan 
darah berlaku, berkemungkinan perubahan tersebut menyumbang kepada 
perkembangan hipertensi dalam SHR. Bagaimana perubahan tersebut menyumbang 
kepada perkembangan hipertensi memerlukan kajian lanjut, terutamanya apabila 
tiada perbezaan ketara dalam tahap MDA dan TAS di tikus WKY dan SHR. Kesan 
pemberian TRF selama 12 minggu tidak dapat menghalang peningkatan tekanan 
darah atau mengubah aktiviti AOE primer di ginjal, walaupun terdapat penurunan 
tahap MDA dan peningkatan tahap TAS.  Kajian menggunakan dos TRF yang lebih 
tinggi atau pecahan TRF secara individu atau bersama-sama dengan antioksidan 
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yang lain perlu dijalankan untuk memastikan peranan TRF dalam menurunkan 
tekanan darah tinggi. 
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ABSTRACT 
 
Although oxidative stress has been implicated in the pathogenesis of 
hypertension in spontaneously hypertensive rats (SHR), the precise status of 
antioxidant enzymes (AOE) and a number of other related parameters such as total 
glutathione (GSH), total anti-oxidant status (TAS) and malondialdehyde (MDA), and 
plasma levels of α-, δ- and γ- tocotrienol during the development of hypertension 
remains unclear.  This study therefore examined the levels of these in the kidneys of 
SHR from the age of 2 to 16 weeks, and the effects of tocotrienol-rich-fraction (TRF) 
supplementation on these and the development of high blood pressure in this species.  
 
Compared to aged-matched WKY rats, catalase (CAT) activity was 
significantly higher from 2 weeks of age, and gluthathione peroxidase (GPx) activity 
was significantly lower from 4 weeks of age in SHR.  A similar pattern was also 
evident in the mRNA expressions.  TAS levels were significantly higher in 4-, 10-, 
12-, and 16-week old SHR while MDA was unchanged except in 16-week old SHR 
where it was significantly higher.  Plasma α-tocotrienol levels were significantly 
lower from the age of 6 weeks and onwards, while plasma γ-tocotrienol levels were 
significantly lower at 12- and 16-week old in SHR. 
 
Compared to age-matched non-supplemented SHR, plasma α-, γ- and δ- 
tocotrienol levels were significantly higher following TRF supplementation in SHR.  
Mean systolic blood pressure was significantly lower at 6 weeks of age in TRF-
supplemented SHR, but was significantly higher at 12 and 16 weeks.  Glutathione 
reductase (GR) and glutathione S-transferase (GST) activities in the kidneys were 
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higher following TRF supplementation in 6, 8 and 10, and 6, 10 and 12-week old 
SHR respectively.  TRF supplementation did not alter the activities of the primary 
AOE in the SHR.  MDA levels were consistently lower in TRF-supplemented SHR.  
TRF supplementation to WKY rats had no effect on blood pressure or the activities 
of primary AOE except superoxide dismutase (SOD) activity and its mRNA levels, 
which were lower in TRF-supplemented WKY rats.  However, GR activity was 
significantly higher in 6, 8 and 10-week old TRF-supplemented WKY rats. 
 
In conclusions, the expression and activities of some of the AOE are altered 
in SHR, from as early as 2 weeks of age, and since these become evident before the 
actual rise in blood pressure it might be inferred that these alterations in some way 
contribute to the development of hypertension in the SHR. Precisely how these 
contribute to the rise in blood pressure needs to be examined further, particularly 
when no obvious differences were evident in the levels of MDA and TAS between 
WKY rats and SHR.  TRF supplementation for 12 weeks neither prevents the rise in 
blood pressure nor significantly alters the kidney primary AOE activities and this 
despite of decreases in the levels of MDA and increases in TAS. Studies using higher 
doses of TRF or its individual fractions or in combination with other antioxidants 
need to be conducted to better ascertain if TRF has a role in reducing high blood 
pressure. 
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CHAPTER ONE 
GENERAL INTRODUCTION    
 
1.1 Free Radicals  
Free radicals are defined as molecules or molecular fragments containing one 
or more molecular unpaired electrons in atomic or molecular orbits (Droge, 2002).  
This unpaired electron gives a considerable degree of reactivity to the free radicals.  
The biologically important free radicals have been divided into either reactive 
oxygen species (ROS) or reactive nitrogen species (RNS) (Droge, 2002).  ROS 
includes superoxide anion (O2•−), hydroxyl radical (•OH), hydrogen peroxide (H2O2), 
hydroperoxyl radical (HO2•), peroxyl radical (RO2•), alkoxyl radical (RO•), 
hypochlorite (HOCL−) and hypochlorus acid (HOCL).  RNS includes nitric oxide 
(NO•/NO), nitrogen dioxide (NO2•), peroxynitrite (ONOO−), peroxynitrous acid 
(ONOOH), alkyl peroxynitrite (ROONO) and nitrothiols (RSNO).  
 
ROS and RNS serve important cellular functions, for example, ROS is 
involved in stimulating several redox-sensitive cellular signaling pathways such as 
opening of ion transport systems, activation of protein phosphorylation and gene 
expressions (Figure 1.1 & 1.2) (Paravicini and Touyz, 2006, Rojas et al., 2006, 
Valko et al., 2007).  These redox-sensitive cellular pathways play important roles in 
the modulation of vascular cell functions such as cell growth, apoptosis, migration, 
angiogenesis and cell adhesions (Yung et al., 2006, Papaharalambus and Griendling, 
2007).  ROS regulates transcriptional factors such as nuclear factor-kappa B (NF-κB) 
and activator protein-1 (AP-1) (Sen and Packer, 1996, Rojas et al., 2006).  NF-κB 
and AP-1 induce expression of pro-inflammatory genes, including monocyte 
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chemotactic protein-1 (MCP-1), adhesion molecules, and interleukins, that plays 
important roles in vascular inflammation, growth, and atherogenic process associated 
with chronic diseases such as hypertension and atherosclerosis (Brigelius-Flohe et 
al., 2004).  NO• is one of the most widespread signaling molecules, and participates 
in numerous cellular functions (Ignarro et al., 1999).  Physiologic levels of NO• 
produced by endothelial cells are essential for regulating the relaxation and 
proliferation of vascular smooth muscle cells, leukocyte adhesion, platelet 
aggregation, angiogenesis, thrombosis, vascular tone, and hemodynamics (Ignarro et 
al., 1999).  
 
ROS has multiple ways of interacting with processes linked to the various 
protein tyrosine phosphorylation-phosphatase systems (Torres, 2003, Chen and 
Keaney, 2004).  The redox processes markedly influence the balance of activities 
between various mitogen-activated protein kinases (MAPK) in vessel wall, such as 
p42/p44 MAPK, stress-activated or c-Jun N-terminal kinase, and the p38 MAPK 
associated pathways.  ROS may inhibit activity of tyrosine phosphatases, resulting in 
increased tyrosine phosphorylation, which influences oxidative stress-induced 
activation of receptor protein tyrosine kinases, such as the epidermal growth factor 
receptor (EGFR), insulin growth factor-1 receptor (IGF-1R), and platelet derived 
growth factor receptor (PDGFR).  It also influences non-receptor tyrosine kinases, 
such as Janus kinase 2 (JAK2), focal adhesion kinase (FAK), phosphoinositide 3-
kinases (PI3-K), all of which have been implicated in cardiovascular remodeling and 
vascular damage (Griendling et al., 2000, Kamata et al., 2000, Droge, 2002).   
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ROS can also modify critical residues in proteins, thereby altering their 
structures and functions.  Oxidative modification of amino acid residues may occur 
in several ways and one such most described modification involves cysteine residues 
(Thannickal and Fanburg, 1995).  Hydroxyl group of cysteine can be oxidized to 
form sulfenic (-SOH), sulfinic (-SO2H), sulfonic (-SO3H) or glutathionylated (-SGH) 
derivatives.  This modification may lower the activity of an enzyme if amino acid 
residues being affected are located in the catalytic domain (Nakashima et al., 2005) 
or decrease the ability of a transcription factor to bind to DNA if the corresponding 
DNA-binding domain is affected (Abate et al., 1990).  
 
ROS is also known to affect calcium channels (Waring, 2005).  H2O2 has 
been proposed to act as an endothelium-derived hyperpolarizing factor (EDHF) that 
is released by the endothelium to cause vasodilatation by opening potassium 
channels in vascular smooth muscle (Sobey et al., 1997, Miura et al., 2003).  Higher 
levels of H2O2 have also been shown to cause calcium-dependent release of NO from 
the endothelium (Yang et al., 1999).  
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Figure 1.1 ROS-targeted signaling molecules (adapted from Yung et al., 2006). 
 
NOTE: (1) ROS regulate activities of several transcription factors, such as, nuclear factor kappa B 
(NF-κB), activator protein-1 (AP-1) and hypoxia-inducible factor-1 (HIF-1), which are involved in the 
regulation of the gene expression. (2) ROS regulate activities of protein tyrosine kinase (PTK) and 
protein tyrosine phosphatase (PTP), which are required in maintaining controlled levels of protein 
phosphorylation. Tyrosine phosphorylation may be increased when cells are exposed to oxidant, due 
to PTP inactivation. (3) Mitogen-activated protein kinase (MAPK) is another target for ROS, which is 
a family of ubiquitous proline-directed, proteinserine/threonine kinases, participating in signal 
transduction classically associated with cell differentiation, growth and death. (4) ROS participate in 
calcium homeostasis by regulating calcium transport system. For example, peroxynitrite inhibits the 
activity of the sacroplasmic reticulum Ca2+-ATPase and H2O2 activates L-type voltage-gated Ca2+ 
channels in SHR. (5) ROS are involved in the modification of proteins by interacting with crucial 
amino acid residues, so as to alter the formation of inter- and intra-molecular bonding, which finally 
affects the conformation and activity of proteins, such as protein kinase C (PKC) isoenzymes.  
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Figure 1.2 Redox-dependent signaling pathways in vascular cells (adapted from 
Touyz and Schiffrin, 2004). 
 
NOTE: Intracellular ROS influence the activity of protein tyrosine phosphatases (PTP) by modifying 
cysteine residues. Oxidation of the cysteine residue to sulfenic acid by H2O2 renders PTPs inactive, 
whereas reduction renders PTPs active. Activated PTP decreases activity of protein tyrosine kinases 
(PTK) and mitogen-activated kinases (MAPK), whereas inactivated PTP have opposite actions. ROS 
also influence gene and protein expression by activating transcription factors, such as NF-κB and AP-
1. ROS stimulate ion channels, such as plasma membrane Ca2+ and K+ channels, leading to changes in 
cation concentration and matrix metalloproteinases (MMPs), which influence extracellular matrix 
proteins (ECM) degradation. Activation of these redox-sensitive pathways results in many cellular 
responses, which if uncontrolled, could contribute to altered vascular tone, increased vascular smooth 
muscle cells (VSMC) growth, inflammation and increased deposition of extracellular matrix protein, 
leading to vascular remodeling in hypertension. Decreased effect (↓) and   increased effect (↑).  
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Under physiological condition, the rate of generation of ROS or RNS appears 
to be balanced with the status of the antioxidant defense or vice versa.  An imbalance 
between ROS or RNS generation and the antioxidants in favour of the former either 
through excessive production of ROS or RNS, or deficient antioxidant function, or 
both, has been ascribed as oxidative or nitrosative stress respectively (Droge, 2002, 
Valko et al., 2007).  During oxidative or nitrosative stress, the excess or non-
neutralised free radicals may interact with a variety of macromolecules including 
lipids, proteins, and nucleic acids resulting in cell dysfunction (Droge, 2002).   In 
addition, most free radicals often have a short half-life ranging from a fraction of a 
second to few seconds (Table 1.1).  The cytotoxic effect of free radicals seems to be 
a critical mediator for many chronic vascular diseases such as hypertension and 
atherosclerosis (Dhalla et al., 2000, Berry et al., 2001).   Thus, there is now a believe 
that there are “two faces” of free radicals in biology in that at physiological levels 
they serve as signaling and regulatory molecules but at high or pathological levels 
they are highly deleterious and cytotoxic oxidants (Valko et al., 2004, Valko et al., 
2007).  
 
     Table 1.1 Half-life of different types of free radical (Devasagayam  et al., 2004). 
 
 
Species   Symbol  Half-life at 370C/second
        
Superoxide   O2•−    1 x 10-6  
Hydroxyl   •OH    1 x 10-9 
Peroxyl    ROO•                                       1 
Hydrogen peroxide  H2O2    stable 
Nitric oxide   NO•    1  
Peroxynitrite   ONOO−   1 x 10-3 
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1.2 Biological Sources of ROS/RNS 
ROS/RNS are derived from various biological sources including, 
mitochondrial electron transport chain, peroxisome, respiratory burst and enzymatic 
sources such as reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, xanthine oxidase, endothelial nitric oxide synthase (eNOS) and 
myeloperoxidase.  
 
Mitochondria generate approximately 2-3 nmol of superoxide/min per mg 
protein.  During mitochondrial respiration, electron transport involves a coordinated 
four electron reduction of oxygen to water in the electron transport chain.  However a 
small number of electrons “leak” prematurely from the mitochondrial respiratory 
chain enzymes forming the oxygen free radical superoxide (McIntyre et al., 1999, 
Cadenas and Davies, 2000).  Measurements of sub-mitochondrial particles suggest 
an upper limit of 1-3% of all electrons in the transport chain “leaking” to generate 
superoxide (McIntyre et al., 1999, Cadenas and Davies, 2000). 
 
Respiratory burst is a defense mechanism against invading organisms.  In this 
process, activated macrophage, monocytes, neutrophils and eosinophils produce 
superoxide, hydrogen peroxide, hydroxyl and hypochlorite to kill microorganisms or 
to inactivate viruses (Halliwell, 1997a).  Activation of cell membrane associated 
NADPH oxidase is involved in the generation of superoxide by reducing molecular 
oxygen during respiratory burst. 
 
Peroxisomes are major sites of oxygen consumption in the cell and participate 
in metabolic functions that utilize oxygen (Valko et al., 2004).  High oxygen 
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consumption leads to H2O2 production, which is then used to oxidize a variety of 
molecules. Additionally, H2O2 is generated in the peroxisome by degradation of 
long-chain fatty acids by fatty acyl-CoA oxidase (Conway et al., 1987, Schrader and 
Fahimi, 2004).  When peroxisomes are damaged and their H2O2 consuming enzymes 
are down-regulated, H2O2 is released into the cytosol, which contributes significantly 
to cell damage associated with oxidative stress. 
 
NADPH oxidase, which was originally found in the phagocytes, is a major 
source of O2•− in endothelial and VSMC (Griendling et al., 2000).  NADPH consists 
of the membrane subunits gp91phox and p22phox and the cytosolic subunits 
p40phox, p47phox, p67phox and GTPase rac1.  NADPH oxidase is up-regulated by 
various stimuli including humoral factors such as angiotensin ll, platelet derived 
growth factor, tumor growth factor-α and hemodynamic forces including laminar and 
oscillatory shear stress (Touyz and Schiffrin, 2004). 
 
eNOS is a cytochrome p450 reductase-like enzyme that catalyzes flavin-
mediated electron transport from the electron donor NADPH to a prosthetic heme 
group (Cai and Harrison, 2000, Schulz et al., 2004).  The enzyme requires 
tetrahydrobiopterin, bound to a nearby heme group, to transfer electron to L-arginine 
to form NO.  In the absence of either tetrahydrobiopterin or L-arginine, eNOS can 
produce O2•− and H2O2 thereby promoting oxidative stress.  This phenomenon has 
been referred to as NOS uncoupling and uncoupling of eNOS diminishes NO 
production and therefore reduces vasodilation (Cai and Harrison, 2000).   
Additionally, eNOS can also become partially uncoupled, such that both O2•− and 
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NO are produced simultaneously resulting in the formation of peroxynitrite (Cai and 
Harrison, 2000).  Under this condition, eNOS may become a peroxynitrite generator. 
 
Xanthine oxidoreductase catalyses the oxidation of hypoxanthine and 
xanthine during purine metabolism (Cai and Harrison, 2000, Schulz et al., 2004).  
Xanthine oxidoreductase exists in two forms, either as xanthine dehydrogenase or as 
xanthine oxidase.  The former reduces nicotinamide adenine dinucleotide (NAD+), 
whereas the latter prefers molecular oxygen, leading to the production of both O2•− 
and H2O2.  This enzyme is not only expressed within cells but also circulates in the 
plasma and binds to endothelial cell extracellular matrix.  Under pathological 
conditions, the enzyme is capable of producing large amounts of ROS. 
 
Myeloperoxidase is a heme-protein expressed in neutrophils and monocytes, 
and secreted during activation of these cells (Wassmann et al., 2004).  
Myeloperoxidase uses H2O2 to produce hypochlorus acid in a 2 step reaction 
involving the redox reaction intermediate compound I (a ferryl/porphyrin radical 
cation). The enzyme also exerts classic peroxide activity and oxidizes a variety of 
organic substrates to reactive oxygen intermediates involving compound I and 
compound II (a ferryl/protein radical species) formations. The important substrates 
are tyrosine and nitrite, resulting in the formation of tyrosyl radicals and nitrogen 
dioxide radicals. 
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1.3 ROS and RNS 
O2•− is primarily produced as a free radical and interacts with other molecules 
to generate secondary ROS, either directly or through enzymes or metal catalyzed 
processes (Valko et al., 2005).  O2•− has a short half life of 10-6 seconds at 37oC 
(Devasagayam et al., 2004).  O2•− is not membrane permeable and therefore its site of 
reaction is limited to the compartment where it is produced (McIntyre et al., 1999).  
O2•− is reduced into H2O2 by superoxide dismutase (SOD). 
 
H2O2 is the non-radical family of ROS as it does not have an unpaired 
electron (Gutteridge, 1995).  Some of the biological functions of H2O2 are activation 
of genes especially those controlled by NF-κB (Sen and Packer, 1996) and induction 
of intracellular calcium (Waring, 2005).  Unlike O2•−, H2O2 is membrane permeable 
and therefore its site of reaction can be different from its site of production.  H2O2 is 
reduced by transient metal ions such as copper and iron to produce hydroxyl radical 
(Young and Woodside, 2001).  Redox state of a cell is largely linked to iron (and 
sometimes copper) redox couple and is maintained within strict physiological limits 
(Valko et al., 2005).  It has been suggested that iron regulation ensures that there is 
no free intracellular iron.  However under oxidative stress, excess superoxide acts as 
an oxidant to release free iron from iron containing molecules (Fe3+ + O2•− → Fe2+ + 
O2).  The released iron reacts with H2O2 in the Fenton reaction (Fe2+ + H2O2 → 
Fe3++ •OH + OH−), generating •OH (Young and Woodside, 2001).  In addition, H2O2 
also reacts with O2•− in the Haber-Weiss reaction (O2•− + H2O2 → O2+ •OH + OH−), 
producing •OH (Haber and Weiss, 1934). Hydroxyl radical is a highly reactive 
substance with a half life of less than 10-9 seconds (Devasagayam et al., 2004).  Due 
to its very short half-life, hydroxyl radical reacts close to its in-vivo site of formation.  
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It interacts with a variety of cellular macromolecules such as protein, lipid, 
carbohydrates and DNA resulting in their damage and subsequent deterioration of 
cell function (Reiter et al., 2000). 
 
Hypochlorous acid (HOCl) is formed by activated neutrophils during 
respiratory burst (Gutteridge, 1995).  The heme-containing enzyme myeloperoxidase 
present in the phagocyte cytoplasm catalyzes the formation of HOCl from H2O2 and 
chloride ions.  HOCl may also give rise to hydroxyl ion by an iron independent or 
iron dependent reaction (Candeias et al., 1993). 
H2O2 + Cl− + H+ → HOCl + H2O 
HOCl + O2•− → •OH + Cl− + O2 
HOCl + Fe2+ →   •OH + Cl− + Fe3+ 
 
The most commonly produced RNS is NO•.  NO• is a small molecule 
containing one unpaired electron on the anti-bonding to 2π*γ orbital.  It is a 
biologically important signaling molecule in several physiological processes, such as 
neurotransmission, blood pressure regulation and in immune defense system 
(Alderton et al., 2001).  NO• has a half life of only a few seconds in an aqueous 
solution (Chiueh, 1999).  NO• is membrane lipid soluble and readily diffuses through 
the cytoplasm and plasma membrane.   It interacts with O2•− to produce peroxynitrite 
anion (Halliwell, 1997b).  The interaction between NO• and O2•− (NO• + O2•− → 
ONOO−) occurs at an extremely rapid rate (6.7 x 109 M-1s-1) (Thomson et al., 1995).  
The reaction is three times faster than the reaction rate of O2•− with SOD (Thomson 
et al., 1995).  Peroxynitrite is a deleterious oxidative molecule that can cause DNA 
fragmentation, lipid and protein oxidation (Halliwell, 1997b).  Peroxynitrite reacts 
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with tyrosine residues in various proteins to produce nitrotyrosine.  Alternatively, 
ROS can activate tyrosine residues to produce tyrosyl radicals that in turn can 
oxidize NO• to produce nitrotyrosine (Eiserich et al., 1995). 
 
In conclusion, both ROS and RNS are highly reactive substances with very 
short half life and with important physiological roles.  Due to their very short half-
life, their reactions are usually close to their in-vivo site of formation.  At 
physiological levels, ROS and RNS are involved in numerous cellular functions. 
However when present in excess they could cause serious deleterious effects to the 
cell structure and function.  This is often referred to as oxidative stress and is 
believed to underly many disease processes.  For optimal cell function, a stable level 
of ROS and RNS at the cellular level is maintained by the antioxidant enzyme and 
non-enzyme systems.     
 
1.4 Antioxidant Enzymes 
Antioxidant enzymes (AOE) constitute and represent an important part of the 
total antioxidant activity of aerobic cells.  The primary AOE in cells include SOD, 
glutathione peroxidase (GPx) and catalase (CAT) (Yu, 1994, Gutteridge, 1995).  
Each of these AOE is known to perform detoxification of a particular ROS.  SOD 
catalyses the conversion of O2•− to H2O2.  CAT and GPx catalyse the decomposition 
of H2O2 into water.  GPx also removes lipid peroxides by conversion of reduced 
glutathione (GSH) to oxidized (GSSG).  Glutathione reductase (GR) regenerates 
GSH from GSSG for reuptake into the GPx reactions. 
SOD is an endogenously produced antioxidant enzyme present in every cell 
in the body (Young and Woodside, 2001) and forms a major cellular defense system 
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against O2•−.  These enzymes contain redox metals (Cu2+ or Mn3+) in the catalytic 
center and dismutate the superoxide radicals to hydrogen peroxide and oxygen (2O2•− 
+ 2H+ + SOD        H2O2 + O2).  Three different isoforms of SOD have been 
identified, namely; the cytosolic copper/zinc-containing SOD (CuZn-SOD, SOD-1) 
(Groner et al., 1985), the mitochondrial manganese-containing SOD (Mn-SOD, 
SOD-2) (Wan et al., 1994), and the extracellular copper/zinc-containing SOD (Ec-
SOD, SOD-3) (Folz and Crapo, 1994). 
 
CuZn-SOD is composed of two identical subunits of about 32 kDA in which 
each subunit containing one copper and one zinc atom is bridged by a histamine 
residue at its active site (McCord and Fridovich, 1969, Mates et al., 1999).  The 
human gene for CuZn-SOD has been localized to the 21q22.1 region of chromosome 
21 and spans around 11 kilo base pairs (bp) (Groner et al., 1985).  CuZn-SOD is 
principally located in the cytosolic, nucleic and lysosomal fractions of the cell.  
CuZn-SOD is believed to play a major role as a first line antioxidant defense system 
and contributes to the most of total SOD activity (Mates et al., 1999). 
 
. Mn-SOD is a homotetramer (96kDa) containing one manganese atom per 
subunit (Weisiger and Fridovich, 1973).  The human gene for Mn-SOD has been 
localized to the 6q25 region of chromosome 6 and spans around 11 kilo bp (Wan et 
al., 1994).  Mn-SOD is found in the mitochondrial fraction of the cell, where it plays 
a central role in catalyzing superoxide anion generated within the mithochondria. 
Mn-SOD is synthesized in the cytoplasm and directed into the mitochondria by cell 
signaling peptides (McIntyre et al., 1999).   
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Ec-SOD is a homotetramer (130kDa) in which each subunit contains one 
copper and one zinc atom (Marklund, 1982).  The human gene for Ec-SOD has been 
localized to chromosome 4 and spans around 5.9 kilo bp (Folz and Crapo, 1994).  It 
is generally produced by fibroblasts, glial and VSMC and secreted into the 
extracellular fluid.  In the vasculature, it is found bound to the surface of endothelial 
cells (Marklund, 1982).  Ec-SOD plays an important role in the regulation of 
oxidative balance in the vascular interstitium by neutralizing superoxide anion.   
 
In general, the SOD iso-enzymes are hydrophobic and are mainly localized 
within cell compartments (Groner et al., 1985, Wan et al., 1994, Folz and Crapo, 
1994) although, to some extent, SOD-3 is also found in the extracellular fluid 
(Marklund, 1982).  SOD-1 and SOD-3 show 50% amino acid homology 
(Hjalmarsson et al., 1987), particularly at the catalytic site (Tainer et al., 1982), but 
neither shows any homology to SOD-2.  SOD-1 and SOD-3 activity is inhibited by 
cyanide, which helps to distinguish these enzymes from SOD-2 (Borders and 
Fridovich, 1985).  Enzymatic activities of SOD-1 and SOD-2 in catalyzing the 
dismutation of superoxide anions have similar efficiencies (Powers and Sen, 2000).  
However enzymatic reaction of SOD-3 against superoxide is reported to be higher 
than that of SOD-1 and SOD-2. 
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Superoxide dismutation ends with the production of a harmful byproduct 
known as H2O2.  To this end, GPx and CAT are frequently used by cells to rapidly 
catalyze the decomposition of H2O2 into less reactive molecules (Yu, 1994, 
Gutteridge, 1995).   
 
GPx catalyzes the reduction of H2O2 and lipid peroxides to water and lipid 
alcohols, utilizing reducing equivalents from GSH in which it is oxidized into GSSG 
(Young and Woodside, 2001). 
H2O2 + 2GSH               GSSG + 2H2O 
    GPx 
 
ROOH + 2GSH                 GSSG + ROH + H2O 
GPx 
 
GPx is a homotetramer (80 kDa) with one selenocysteine residue in each 
monomer (Forstrom et al., 1978).   It requires selenium in the form of selenocysteine 
at the active site for its catalytic function.  GPx is located in the membrane, nucleas, 
mitochondria, cytosol and other organelles of cells (Powers and Sen, 2000).  The fact 
that GPx is distributed well, allows it to rapidly remove deleterious oxidant 
substances from a variety of cell sources.  This characteristic makes GPx an 
important cellular protectant against ROS mediated damage to membrane lipids, 
proteins and nucleic acids.  Five isoforms of this enzyme have been identified.  They 
are cytsolic GPx (Flohe et al., 1973), phospholipid hydroperoxide GPx (Ursini et al., 
1982), plasma form of GPx (Takahashi and Cohen, 1986), gastrointestinal form of 
GPx (Chu et al., 1993), and non-selenium dependent GPx (Fisher et al., 1999).  
Cytosolic GPx is present predominantly in erythrocytes, kidney and liver, and 
phospholipid hydroperoxide GPx is highly expressed in renal epithelial cells and 
testes (Mates et al., 1999).  Plasma form of GPx is also believed to be produced by 
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the kidney (Roxborough et al., 1999).   All GPx isoforms reduce H2O2 and alkyl 
hydroperoxides but differ in their specificities against hydroperoxide (Mates et al., 
1999). 
 
CAT catalyzes the decomposition of H2O2 to water and oxygen molecules 
(Mates et al., 1999).  CAT is a tetramer with a molecular weight of (240 kDa) and 
each subunit contains a haem group and NADPH molecule (Mates et al., 1999).  It 
needs iron as a cofactor bound to the active site for its catalytic activity. 
2H2O2                2H20 + O2  
CAT 
 
CAT has one of the highest turnover rates of all enzymes; one molecule of 
CAT can convert millions of molecules of H2O2 to water and oxygen per second 
(Powers and Sen, 2000).  By removing H2O2, it indirectly detoxifies O2•−, which have 
been turned into H2O2 by SOD.  CAT is an intracellular AOE that is largely located 
in cellular peroxisomes and to some extent in the cytosol and intracellular granules 
(Young and Woodside, 2001).  Thus, CAT mainly decompensates H2O2, which is 
produced within the peroxisome.  Under physiological conditions, peroxisome is 
known to produce H2O2, but not O2•− (Valko et al., 2004). Higher oxygen 
consumption in the peroxisome leads to H2O2 production.  The high content of CAT 
in this organelle prevents the accumulation of this toxic compound.   However, when 
CAT activity is insufficient, H2O2 generated within peroxisome will be released into 
the cytosol, which then contributes to oxidative stress. 
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Although there is some overlap between the functions of CAT and GPx, the 
two enzymes differ in their affinity for H2O2.  Mammalian GPx has a greater affinity 
for H2O2 at lower concentrations compared to CAT (Powers and Sen, 2000).  This 
means at low steady state substrate concentrations, GPx plays a more prominent role 
in removing H2O2, and at high substrate concentrations, CAT plays a greater 
effective role in removing H2O2 (Gutteridge, 1995).  Therefore, GPx is thought to be 
a major defense mechanism in low level of oxidative stress and CAT is effective in 
high level of oxidative stress or in the case of limited GPx reaction in protecting cells 
from H2O2 (Wassmann et al., 2004).  In the absence of adequate activity of these 
enzymes, H2O2 and lipid peroxides are converted to hydroxyl radicals and lipid 
peroxyl radicals, respectively, by transition metals (Gutteridge, 1995).  Hydroxyl 
radical is a highly toxic radical and damage sustained as a consequence of free 
radicals is often largely caused by the devastating effect of hydroxyl radical.  Unlike 
H2O2, hydroxyl radical is not enzymatically detoxified and membrane impermeable, 
thus it interacts with macromolecules within its site of generation and the radical 
damage is often referred as site specific (Reiter et al., 2000). 
 
GR is a dimer of two identical subunits of molecular mass 50 kD each 
(Gutterer et al., 1999).  GR requires NADPH as coenzyme for its catalytic activity 
and possesses one flavin molecule at its catalytic site.  GR catalyses the reduction of 
GSSG to GSH using NADPH as an electron donor (Fridovich, 1978).  The ratio of 
GSH to GSSG is kept very high by the enzymatic activity of GR and a low ratio of 
GSH/GSSH is an index that indicates tissue oxidative damage.   
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GST has a molecule weight of 45 kD and is dissociable into two subunits of 
approximately 25 kD (Habig et al., 1974).  Four classes of GST have been identified 
including alpha (α), mu (µ), pi (π) and theta (θ). (Board et al., 1990).  GST is a 
selenium-independent enzyme and it accepts a broad spectrum of organic 
hydroperoxides as substrates except H2O2 (Burk et al., 1978).  GST plays a major 
role in the detoxification process by catalyzing the conjugation of GSH to various 
electrophilic substrates (Habig et al., 1974). 
 
The activities of AOE are closely dependent to each another and coordination 
of their functions results in the maintenance of ROS below critical levels compatible 
with cell viability (Droge, 2002).  These enzymes are tightly regulated in maintining 
a steady redox state to keep the entire system in a fully functioning state.  Any 
disturbance of this tightly balanced system would lead to promotion of oxidation. 
 
In addition to that, oxidative status of the cell may regulate the gene 
expression and activity of these AOE (Franco et al., 1999, Rodriguez et al., 2004).  
Moderate amount of radical stress stimulates the AOE reaction as an adaptive 
mechanism (Gechev et al., 2002).  For instant, total SOD, Mn-SOD, GPx and CAT 
activities were reported to be increased by two fold in the renal tissue following 
oxidant injury (Yoshioka et al., 1990).  However, exposure to greatly elevated 
oxidative stress on the other hand may reduce the enzymatic activities by inactivating 
or inducing degradation of these enzymes (Pigeolet et al., 1990, Pigeolet and 
Remacle, 1991, Wei and Lee, 2002).  High concentration of substrates including 
H2O2 and hydroperoxides have been found to inhibit GPx activity by 50 % while 
CAT activity was inactivated by •OH and O2•−, and SOD activity was inhibited by 
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H2O2 (Pigeolet et al., 1990).  In certain circumstances, the alteration of these AOE 
during oxidative stress is insufficient to neutralize the harmful effects of free radicals 
(Droge, 2002).  For example, excessive production of O2•− may elevate SOD activity 
as a compensatory mechanism.  However, induction of one enzyme may not 
necessarily lead to the induction of the other enzymes (Amstad et al., 1991) e.g. in 
the case of mitigated GPx/CAT activity.  Through a negative feedback mechanism, 
increasing amount of H2O2 will slowly inactivate SOD activity.  Eventually, a 
deficiency or failure in the up-regulation of AOE activities will enhance oxidative 
stress resulting in tissue oxidant injury. 
 
In summary, to counteract the deleterious effects of free radicals and other 
ROS or RNS, all cells are endowed with their own antioxidant systems that help 
contain the free radical activity within normal range.  The levels of these AOE are 
tuned to match the production of free radicals.  Any disturbance in this matching 
results in significant deleterious effects on the cells. 
 
1.5 Vitamin E (Tocotrienol) 
Vitamin E includes 8 different isoforms, the tocopherols (α, β, δ, λ) and the 
tocotrienols (α, β, δ, λ) (Schaffer et al., 2005).  The tocotrienol and tocopherol share 
a similar aromatic chromonal nucleus/head and a hydrocarbon side chain.  The 
various isoforms of vitamin E (α, β, δ, λ) differ only in their methyl substituents on 
the chromonal nucleas.  The difference between tocotrienols and tocopherols is in 
their corresponding aliphatic tails.  Tocopherols have a saturated phytol chain, 
whereas tocotrienols have an unsaturated isoprenoid chain with double bonds at 3, 7 
and 11 positions of the hydrocarbon tail (Schaffer et al., 2005). 
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 Vitamin E is incorporated into cellular membranes, where it inhibits the 
peroxidation of lipids by scavenging the chain propagating peroxyl radicals (Packer 
et al., 2001).  Vitamin E is the primary chain breaking antioxidant in cell 
membranes.  Because of its high lipid solubility, it is associated with lipid rich 
membranes such as those of the mitochondria, sarcoplasmic reticulum and plasma 
membrane.  The hydroxyl group of the vitamin E gives up its hydrogen atom to 
peroxyl radical and converts it to lipid peroxide and stops the propagation of lipid 
free radicals.  Hence, vitamin E is a chain breaking antioxidant, it breaks the chain 
reaction of lipid peroxidation but itself gets converted into a radical during the 
process.  Vitamin E consumed in this scavenging process is regenerated by vitamin C 
(Figure 1.3) (Packer et al., 2001). 
 
Antioxidant properties of tocotrienol in scavenging free radicals were found 
to be higher than the tocopherols.  α-tocotrienol possesses 40-60 times higher 
antioxidant activity against (Fe2+ & NADPH) induced lipid peroxidation in rat liver 
microsomal membranes than α-tocopherol (Serbinova et al., 1991).  α-tocotrienol 
protection of cytochrome P450 againts oxidative damage was 6.5 times greater than 
α−tocopherol (Serbinova et al., 1991).  α-tocotrienol also exhibits significantly 
greater peroxyl scavenging potency than α-tocopherol in phosphatidylcholine 
liposomes (Suzuki et al., 1993).  It is suggested that antioxidant potency of α-
tocotrienol requires a membrane environment, as incidently both antioxidants have 
identical activity when estimated in hexane in-vitro (Suzuki et al., 1993).  The 
superior antioxidant activity of tocotrienols is due to its higher recycling efficiency 
of chromanoxyl radicals and a uniform distribution and stronger disordering in 
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membrane bilayers, which makes the interaction between chromanols and lipid 
radicals more efficient (Serbinova et al., 1991).    
 
 
 
 
* 1) Thiol transferase (glutaredoxin)  
   2) Glutathione (GSH)- dependent dehydroascorbate reductase 
   3) Protein disulfide isomerase 
   4) Thioredoxin (TRX) reductase 
Figure 1.3 The antioxidant network showing the interaction among vitamin E, 
vitamin C and thiol redox cycles (Packer et al., 2001). 
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1.6 Total Anti-oxidant Status 
Total anti-oxidant status (TAS) indicates the capacity of both enzymatic 
(such as  CuZn-SOD, Mn-SOD, CAT, GPx, GST, thioredoxin reductase and 
cytochrome oxidase) and non-enzymatic antioxidants (such as  vitamin E, β-
carotene, ubiquinol, transferrin, lactoferrin, albumin, haptoglobins, GSH, bilirubin, 
uric acid and vitamin C) to scavenge free radicals in biological samples (Gutteridge, 
1995, Mates et al., 1999, Young and Woodside, 2001).  Antioxidant protections can 
occur at several different levels within cells, some of which include  preventing free 
radical formation, intercepting radicals when formed, repairing oxidative damage 
caused by radicals, increasing the elimination of damaged molecules, and not 
repairing excessively damaged molecules to minimize the introduction of mutations 
(Gutteridge, 1995, Mates et al., 1999, Young and Woodside, 2001).   
 
1.7 Oxidative Stress & Hypertension 
An imbalance between free radical production and antioxidant activity, often 
referred to as oxidative stress, has been implicated in some cardiovascular disease 
states like hypertension (Diaz et al., 1997, Vaziri and Rodriguez-Iturbe, 2006, 
Ceriello, 2008).  Elevated levels of markers of oxidative stress including, 8-
deoxyguanosine, lipid peroxidation and GSSG/GSH ratio have been reported in 
patients with essential hypertension (Redon et al., 2003, Abdilla et al., 2007, Rodrigo 
et al., 2007).  The activities of SOD, CAT and GPx have also been found to be 
significantly decreased in whole blood and peripheral mononuclear cells of 
hypertensive individuals (Redon et al., 2003, Abdilla et al., 2007).   
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Oxidative stress has been associated with hypertension via several 
mechanisms.  These include both structural (Baas and Berk, 1995, Rojas et al., 2006, 
Papaharalambus and Griendling, 2007) and functional changes in the vasculature 
(Cai and Harrison, 2000) (Figure 1.4).  Oxidative stress mediates structural changes 
through stimulation of growth signaling cascades in the vascular endothelial or 
smooth muscle cells (Rojas et al., 2006, Papaharalambus and Griendling, 2007), 
which promote vascular cell proliferation, hypertrophy and collagen deposition 
leading to the thickening of vascular media, narrowing of vascular lumen and 
consequently increasing resistance to blood flow.  In SHR, a model of essential 
hypertension (Dickhout and Lee, 1998), evidence of pre-glomerular structural 
changes and greater renal vascular resistance has been reported as early as 4 weeks of 
age, before the rise in arterial pressure (Smeda et al., 1988, Christiansen et al., 2002).  
Renal vascular resistance was demonstrated to begin to increase from 4 weeks of age 
and to remain elevated in older age groups of SHR when compared to age-matched 
WKY rats (Christiansen et al., 2002).  In addition, 6 weeks old SHR showed an 
increase in resistance in pre-glomerular vessels and efferent arterioles and a 
reduction in renal blood flow with a concomitant rise in blood pressure (Dilley et al., 
1984).  
 
ROS mediates the functional alteration of blood vessels by inactivating NO, 
thereby promoting vasoconstriction (Cai and Harrison, 2000) (Figure 1.5). Under 
physiological conditions, NO is released from endothelial cells and causes dilatation 
of blood vessels by increasing intracellular cyclic guanosine monophosphate (cGMP) 
concentration, which then inhibits calcium influx and mobilization from intracellular 
stores, thereby facilitating vascular smooth muscle relaxation.  However, in oxidative 
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stress, O2•− may interact with NO resulting in reduced NO bioavailability.  Studies 
seem to suggest that hypertensive rats have reduced endothelial dependent 
vasodilation in several vascular beds including kidney, that has been ascribed in part 
to decrease NO activity (Mayhan, 1990, Ito et al., 1992). Cultured endothelial cells 
from the aorta of 5 weeks old SHR had significantly lower NO release with an 
increase in O2•− production (Grunfeld et al., 1995).  Similarly, both cultured VSMC 
and endothelial cells from SHR aorta had an apparent decrease in NO release 
(Malinski et al., 1993).   Administration of tempol lowered blood pressure and 
increased NO bioavailability in SHR (Schnackenberg et al., 1998).  In addition to 
decreased levels of NO, reaction between O2•− and NO may lead to the production of 
peroxynitrite, an oxidant species, which further potentiates tissue injury (Halliwell, 
1997b).  Peroxynitrite converts tyrosine residues to nitrotyrosine, which is also a foot 
print of NO interaction with O2•−. 
 
 
 
Figure 1.4 Systemic and renal pro-hypertensive role of ROS and vascular reactivity (adapted 
from Rodriguez-Iturbe et al., 2004b).  
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